SK pharmteco Partners with NIH and Axle Informatics to Advance Rare Disease Gene Therapies
核心洞察
SK pharmteco (搜索) has formed a strategic partnership with the National Institutes of Health and Axle Informatics (搜索) to accelerate gene therapy development for rare diseases through viral vector programs.
The collaboration focuses on manufacturing lentiviral vectors (搜索) for treating rare inherited blood and metabolic disorders, with SK pharmteco (搜索) producing drug substance for ex vivo transduction of patients' CD34+ hematopoietic stem cells (搜索).
This partnership demonstrates how integrated collaborations between contract manufacturers and public research institutions can help translate academic research into clinical applications for patients with serious unmet medical needs.
SK pharmteco (搜索) announced a strategic partnership with Axle Informatics (搜索) and the National Institutes of Health (NIH) to advance gene therapy development for rare diseases, marking a significant collaboration between the contract development and manufacturing organization and leading public research institutions. The partnership, announced on May 7, 2026, focuses specifically on viral vector programs and underscores the company's commitment to addressing unmet medical needs in the rare disease sector.
Partnership Structure and Objectives
As a subcontractor to the NIH, SK pharmteco (搜索) is working with Axle Informatics (搜索), the NIH's primary contractor, to accelerate the translation of academic research into clinical practice. The collaboration combines SK pharmteco's advanced manufacturing capabilities with leading principal investigators at the NIH to address significant unmet medical needs in rare disease treatment.
"Collaborating with the NIH and Axle Informatics (搜索) marks an important step in our efforts to support patients with rare diseases," said John Lee, Global Head of Viral Vector at SK pharmteco (搜索). "Rare disease programs often operate under significant development and funding constraints, making reliable technical execution and flexible partnerships especially important."
Focus on Lentiviral Vector Manufacturing
The inaugural program under this partnership centers on producing lentiviral vectors (搜索) (LVV) to treat rare inherited blood and metabolic disorders. SK pharmteco (搜索) has worked closely with NIH investigators to advance this effort, manufacturing drug substance intended for future ex vivo transduction of patients' CD34+ hematopoietic stem cells (搜索).
The company has managed batch-release testing for these programs, with most analytical assays performed in-house at its specialized laboratories. This approach demonstrates the integration of manufacturing and analytical capabilities necessary for complex gene therapy development.
Industry Impact and Strategic Positioning
Gary Mays, Chief Operating Officer at Axle Informatics (搜索), emphasized the collaborative model's potential impact: "This effort illustrates how integrated partnerships can accelerate the advancement of translational research into clinical outcomes. Axle is focused on connecting capabilities across the NIH environment, and our collaboration with SK pharmteco (搜索) adds essential manufacturing strength to help NIH advance promising gene therapies for patients in need."
The partnership highlights SK pharmteco (搜索)'s positioning as a technical partner for both emerging biotech firms and large-scale public institutions. The collaboration reflects the company's broader strategy to support rare disease innovators through partnership models designed to advance complex programs into clinical development.
Manufacturing and Development Capabilities
SK pharmteco (搜索) brings specialized viral vector development, manufacturing, and analytical support to the partnership. The company operates as a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea.
The company's core capabilities center on small molecules, peptides, and viral vectors, providing specialized expertise for complex therapies. Through these capabilities, SK pharmteco (搜索) supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide.
This collaboration was funded in part by the National Institutes of Health, demonstrating the public sector's investment in advancing gene therapy development for rare diseases through strategic partnerships with specialized manufacturing organizations.